Grufity logoGrufity logo
StocksFundsSearch Filings

United Therapeutics Corp Stock Research

UTHR

217.22USD+3.74(+1.75%)Market Closed

Market Summary

USD217.22+3.74
Market Closed
1.75%

UTHR Alerts

UTHR Stock Price

UTHR RSI Chart

UTHR Valuation

Market Cap

10.1B

Price/Earnings (Trailing)

13.95

Price/Sales (Trailing)

5.12

EV/EBITDA

8.74

Price/Free Cashflow

14.05

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

49.09%

Return on Equity

15.16%

Return on Assets

12.03%

Free Cashflow Yield

7.12%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

9.74%

Revenue Q/Q

3.13%

UTHR Earnings

Earnings (TTM)

727.3M

Earnings Y/Y

17.74%

Earnings Q/Q

-44.8%

Price Action

52 Week Range

201.65283.09
(Low)(High)

Last 7 days

4.8%

Last 30 days

-0.5%

Last 90 days

-12.6%

Trailing 12 Months

-4.8%

UTHR Financial Health

Current Ratio

9.85

UTHR Investor Care

Shares Dilution (1Y)

3.12%

Diluted EPS (TTM)

14.83

Peers (Alternatives to United Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
309.8B
1.6B
-14.20% 63.79%
-161.61
198.97
77.54% 1.62%
285.4B
56.7B
-8.29% -4.90%
24.12
4.92
0.03% -39.22%
87.6B
12.4B
-7.87% 17.32%
20.2
7.2
-25.07% -47.28%
86.0B
9.2B
-3.63% 23.60%
26.37
9.33
15.86% 32.99%
24.1B
1.0B
-2.92% 54.32%
-22.59
23.19
22.88% -19.27%
11.7B
975.7M
-0.22% 72.44%
-10.45
11.95
27.41% -212.78%
10.1B
2.0B
-0.54% -4.82%
13.95
5.12
12.05% 52.86%
MID-CAP
4.8B
-
-14.71% 282.83%
-15.1
2.5K
- -27.52%
3.6B
363.3M
17.36% 1.78%
-5.05
9.82
3.39% -55.81%
3.5B
204.6M
12.22% 2.64%
-6.05
17.19
-7.52% 10.65%
2.2B
18.9M
-15.43% -4.97%
-3.02
117.75
- -16.17%
SMALL-CAP
3.7B
-
-1.80% -6.60%
-8.5
38.73
34.30% -67.22%
1.2B
256.5M
-30.42% 62.68%
12.31
4.77
66.85% 120.61%
300.5M
165.3M
-29.46% 47.27%
-3.29
1.82
130.70% 57.97%
41.5M
-
15.88% 3252.62%
-0.82
19.11
- -29.84%

Financials for United Therapeutics

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue2.3%1,9811,9361,8601,7891,768
Gross Profit3.7%1,7231,6611,633--
  S&GA Expenses-4.3%480501---
  R&D Expenses4.3%337323312325305
Costs and Expenses5.1%1,005957886900860
EBITDA4.7%1,034988875939-
EBITDA Margin0.6%0.53*0.53*0.49*0.53*-
Earnings Before Taxes-1.8%934951912804870
EBT Margin0.1%0.49*0.49*0.45*0.49*-
Interest Expenses28.1%42.0032.0025.0020.0019.00
Net Income2.8%727707631687-
Net Income Margin-1.2%0.38*0.38*0.35*0.39*-
Free Cahsflow-2.3%664679652673-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets5.0%6,3466,0455,7825,5435,360
  Current Assets-5.5%3,1933,3803,0562,6842,587
    Cash Equivalents21.0%1,164961967795813
  Inventory0.5%10310291.0090.0088.00
  Net PPE4.1%897862841791784
Liabilities-2.0%1,2231,2481,2191,2251,184
  Current Liabilities-5.4%325343316332293
Shareholder's Equity6.8%5,1234,7974,5624,3184,176
  Retained Earnings4.8%5,2835,0424,9104,6714,555
  Additional Paid-In Capital2.9%2,4572,3882,3152,2922,254
Accumulated Depreciation3.4%377364352--
Shares Outstanding1.4%47.0046.0046.0045.0045.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations10.7%889803849776797
  Share Based Compensation8.1%11610787.0011477.00
Cashflow From Investing17.0%-673-811-818-959-839
Cashflow From Financing79.0%13575.0027.0037.0024.00

Risks for UTHR

What is the probability of a big loss on UTHR?

72.3%


Probability that United Therapeutics stock will be more than 20% underwater in next one year

28.1%


Probability that United Therapeutics stock will be more than 30% underwater in next one year.

12.7%


Probability that United Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does UTHR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if United Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for UTHR

Cumulative Returns on UTHR

12.8%


10-Year Cumulative Returns

9.3%


7-Year Cumulative Returns

15.2%


5-Year Cumulative Returns

20.8%


3-Year Cumulative Returns

What are the long-term rolling returns for UTHR?

FIve years rolling returns for United Therapeutics.

Annualized Returns

Which funds bought or sold UTHR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-06-01
MACQUARIE GROUP LTD
reduced
-21.34
-12,176,000
20,725,000
0.03%
2023-05-30
Aspire Private Capital, LLC
reduced
-10.34
-2,242
5,823
-%
2023-05-26
ProShare Advisors LLC
reduced
-18.51
-694,535
1,326,070
-%
2023-05-23
BROOKFIELD Corp /ON/
sold off
-100
-7,932,520
-
-%
2023-05-23
Seaport Global Advisors, LLC
added
8.33
-69,001
471,884
1.49%
2023-05-23
ROYCE & ASSOCIATES LP
unchanged
-
-541,300
2,239,600
0.02%
2023-05-23
Capital Impact Advisors, LLC
sold off
-100
-277,534
-
-%
2023-05-23
Toroso Investments, LLC
added
190
3,499,000
6,108,000
0.10%
2023-05-22
Raleigh Capital Management Inc.
sold off
-100
-10,289
-
-%
2023-05-22
EMC Capital Management
unchanged
-
-136,000
563,000
0.47%

1–10 of 44

Latest Funds Activity

Are funds buying UTHR calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own UTHR
No. of Funds

United Therapeutics News

MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of ....
MarketBeat,
111 seconds ago
Zacks Investment Research
United Therapeutics (UTHR) Q1 Earnings Beat Estimates.
Zacks Investment Research,
31 days ago

Schedule 13G FIlings of United Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 08, 2023
blackrock inc.
10.2%
4,726,986
SC 13G/A
Feb 14, 2023
avoro capital advisors llc
6.3%
2,865,000
SC 13G/A
Feb 13, 2023
renaissance technologies llc
5.14%
2,344,492
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.83%
4,480,719
SC 13G/A
Feb 06, 2023
wellington management group llp
5.64%
2,569,263
SC 13G
Feb 02, 2023
rothblatt martine a
8.0%
3,919,603
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
4,510,211
SC 13G/A
Feb 11, 2022
renaissance technologies llc
6.48%
2,917,191
SC 13G/A
Feb 11, 2022
avoro capital advisors llc
6.7%
3,035,000
SC 13G/A

UTHR Fair Value

Show Fair-Value

Recent SEC filings of United Therapeutics

View All Filings
Date Filed Form Type Document
Jun 01, 2023
144
Notice of Insider Sale Intent
Jun 01, 2023
4
Insider Trading
May 31, 2023
SD
SD
May 23, 2023
4
Insider Trading
May 18, 2023
144
Notice of Insider Sale Intent
May 18, 2023
4
Insider Trading
May 11, 2023
4
Insider Trading
May 08, 2023
4
Insider Trading
May 05, 2023
144
Notice of Insider Sale Intent
May 04, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for UTHR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-06-01
MAHON PAUL A
sold
-1,254,680
209
-6,000
evp & general counsel
2023-06-01
MAHON PAUL A
acquired
721,560
120
6,000
evp & general counsel
2023-05-22
Giltner Richard
acquired
319,500
63.9
5,000
-
2023-05-22
Giltner Richard
back to issuer
-1,092,950
218
-5,000
-
2023-05-18
MAHON PAUL A
sold
-1,287,470
214
-6,000
evp & general counsel
2023-05-18
MAHON PAUL A
acquired
721,560
120
6,000
evp & general counsel
2023-05-10
PATUSKY CHRISTOPHER
back to issuer
-424,480
212
-2,000
-
2023-05-10
PATUSKY CHRISTOPHER
acquired
176,060
88.03
2,000
-
2023-05-05
Mesa Nilda
sold
-80,337
214
-374
-
2023-05-04
MAHON PAUL A
sold
-1,294,900
215
-6,000
evp & general counsel

1–10 of 50

Martine A. Rothblatt
960
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Income Statement

2023-03-31
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Total revenues$ 506.9$ 461.9
Operating expenses:  
Cost of sales52.325.9
Research and development82.969.0
Selling, general, and administrative87.379.0
Total operating expenses222.5173.9
Operating income284.4288.0
Interest income29.24.3
Interest expense(13.8)(4.7)
Other (expense) income, net(7.9)22.8
Impairment of investment in privately-held company0.0(1.7)
Total other income, net7.520.7
Income before income taxes291.9308.7
Income tax expense(51.0)(68.8)
Net income$ 240.9$ 239.9
Net income per common share:  
Basic (in dollars per share)$ 5.20$ 5.31
Diluted (in dollars per share)$ 4.86$ 5.03
Weighted average number of common shares outstanding:  
Basic (in shares)46.345.2
Diluted (in shares)49.647.7

UTHR Balance Sheet

2023-03-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,163.5$ 961.2
Marketable investments1,699.91,877.5
Accounts receivable, no allowance for 2023 and 2022134.5220.4
Inventories, net102.5102.0
Other current assets92.6219.2
Total current assets3,193.03,380.3
Marketable investments1,765.61,316.2
Goodwill and other intangible assets, net44.544.5
Property, plant, and equipment, net896.5861.5
Deferred tax assets, net321.9327.7
Other non-current assets124.5114.3
Total assets6,346.06,044.5
Current liabilities:  
Accounts payable and accrued expenses239.7229.9
Share tracking awards plan46.380.8
Other current liabilities38.632.5
Total current liabilities324.6343.2
Line of credit800.0800.0
Other non-current liabilities98.2104.6
Total liabilities1,222.81,247.8
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued0.00.0
Common stock, par value $.01, 245,000,000 shares authorized, 73,317,754 and 72,651,280 shares issued, and 46,698,538 and 46,032,064 shares outstanding as of March 31, 2023 and December 31, 2022, respectively0.70.7
Additional paid-in capital2,457.32,388.4
Accumulated other comprehensive loss(38.8)(55.5)
Treasury stock, 26,619,216 shares as of March 31, 2023 and December 31, 2022(2,579.2)(2,579.2)
Retained earnings5,283.25,042.3
Total stockholders’ equity5,123.24,796.7
Total liabilities and stockholders’ equity$ 6,346.0$ 6,044.5